Pegfilgrastim to help Kyowa Kirin weather biosimilar G-CSFs?
This article was originally published in Scrip
In a move that should help it cope over the longer term with competition from newly launched biosimilar filgrastims in Japan, Kyowa Hakko Kirin has filed for the approval in this market of KRN125 (pegfilgrastim), its long-acting form of the granulocyte colony-stimulating factor (G-CSF).
You may also be interested in...
Japanese companies agree to discontinue regenerative cell therapy pact after high-profile Phase II failure, but SanBio will move ahead with development and Dainippon will hold onto ex-partner stake for now.
Asia Deal Watch: RAPT And Hanmi Partner On CCR4 Antagonist Offering Potential In Multiple Cancer Types
RAPT can earn up to $108m in milestones plus sales royalties under the deal. BerGenBio, Piramal partner on developing AML therapy.
Japanese company starts pivotal trial with novel molecule as it looks to build oncology presence.